Making CES history, Abbott (NYSE: ABT) presented a keynote at the most influential tech event in the world, the first healthcare company ever to do so.
| LAS VEGAS, Jan. 6, 2022 /PRNewswire/ -- Making CES history, Abbott Laboratories (NYSE: ABT) presented a keynote at the most influential tech event in the world, the first healthcare company ever to do so. Abbott Chairman and Chief Executive Officer Robert B. Ford headlined the event, “Human-Powered Health: Unlocking the Possibility of You.” “Technology gives us the power to digitize, decentralize and democratize healthcare, create a shared language between you and your doctor – and put more control of your health in your hands,” Mr. Ford said. “We’re creating a future that will bring you and your loved ones care that’s more personal and precise. It’s happening right now. And its potential is no less than incredible.” Lingo – Speaking Your Body’s Unique Language During the keynote, the company announced it’s developing a new category of consumer biowearables called Lingoi. These biowearables are being designed to translate your body’s unique language into actionable data to help you track and measure your general health and wellness. The sensor technology is being designed to track key signals in the body such as glucose, ketones and lactate, and could also be used one day to track alcohol levels. “This will be like having a window into your body,” Mr. Ford said. “It’s science that you will be able to access any time so you can understand what your body is telling you and what it needs. Our vision is that Lingo will go far beyond today’s wearables for consumers to help you proactively manage your health, nutrition and athletic performance.” Lingo extends the Abbott sensing technology platform that Abbott pioneered in 2014 for people with diabetes, allowing people to continuously monitor their glucose levels with a small sensor on the back of the upper arm. Actress and comedian Sherri Shepherd shared live on the CES stage how FreeStyle Libre 2 changed her life, giving her glucose readings, right on her smartphoneii, unique to her body so she can make healthier decisions. Abbott then built this technology platform to develop a product designed for athletes with the 2020 launch of Libre Sense Glucose Sport Biowearableiii in Europe. Elite athletes, like marathon world record holder Eliud Kipchoge, use this biowearable to optimize how they fuel their bodies for rigorous training. Lingo aims to expand glucose monitoring to people looking to manage their weight, sleep better, improve energy and think clearer. Abbott is designing Lingo to measure other biomarkers beyond glucose in the future. A ketone biowearable is being developed to track ketones continuously, see how fast you are getting into ketosis, and understand exactly what keeps you there by providing insights on dieting and weight loss. A lactate biowearable is in development to track continuous lactate build up during exercise, which can be used as an indicator of athletic performance. A Human Focus Beyond those who demonstrated the human impact of Abbott’s sensors, Mr. Ford was joined on stage by people whose lives were impacted by Abbott devices, partners who rallied to provide seamless and safe travel experiences and other visionaries in the industry.
Indications and Important Safety Information About Abbott Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews. i The Lingo portfolio of products are under development and are not intended for medical use. They are not intended for use in screening, diagnosis, treatment, cure, mitigation, prevention, or monitoring of diseases. Lingo Portfolio of products are not for sale in the U.S. ii The FreeStyle Libre 2 app is only compatible with certain mobile devices and operating systems. Please check our website for more information about device compatibility before using the app. Use of the FreeStyle Libre 2 app requires registration with LibreView. iii The Libre Sense Biosensor is not available in the United States and not intended for medical use. iv The HeartMate 3 Left Ventricular Assist System is indicated for providing short- and long-term mechanical circulatory support in adult and pediatric patients with advanced refractory left ventricular heart failure and with an appropriate body surface area. Prior to using this device, please review the Instructions for Use at https://www.cardiovascular.abbott/us. Views expressed are the patient’s own. v The CardioMEMS™ HF System is indicated for wirelessly measuring and monitoring pulmonary artery (PA) pressure and heart rate in New York Heart Association (NYHA) Class III heart failure patients who have been hospitalized for heart failure in the previous year. The hemodynamic data are used by physicians for heart failure management and with the goal of reducing heart failure hospitalizations. Prior to using this device, please review the Instructions for Use at https://www.cardiovascular.abbott/us. Views expressed are the patient’s own. vi The BinaxNOW™ COVID-19 Ag Card Home Test has received U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA). This product has not been FDA cleared or approved but has been authorized by FDA under an EUA. This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of IVDs for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
SOURCE Abbott | ||
Company Codes: NYSE:ABT |
View original content:
